start page     |    register     |    log-in    |    tools

Professor Morris Brown (pubs from 1996)

Genome-wide association study identifies novel genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia
Am J Hum Genet. 2008 Jan 10; 82(1) pp. 139 - 149
Chris Wallace; Stephen J Newhouse; Peter Braund; Feng Zhang; Martin Tobin; Mario Falchi; Kourosh Ahmadi; Richard J Dobson; Ana Carolina B Marçano; Cother Hajat; Paul Burton; Panagiotis Deloukas; Morris Brown; John M Connell; Anna Dominiczak; G Mark Lathrop; John Webster; The Wellcome Trust Case Control Consortium; Martin Farrall; Tim Spector; Nilesh J Samani; Mark J Caulfield; Patricia B. Munroe

Genomewide association analysis of coronary artery disease.
N Engl J Med. 2007 Aug 2;357(5):443-53. Epub 2007 Jul 18.
Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, König IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H, WTCCC

Genetic association analysis of inositol polyphosphate phosphatase-like 1 (INPPL1, SHIP2) variants with essential hypertension.
J Med Genet. 2007 Jun 8; [Epub ahead of print]
Braga Marcano AC, Burke B, Gungadoo J, Wallace C, Kaisaki PJ, Woon PY, Farrall M, Clayton D, Brown M, Dominiczak A, Connell JM, Webster J, Lathrop M, Caulfield M, Samani N, Gauguier D, Munroe PB.

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature. 2007 Jun 7;447(7145):661-78.
Wellcome Trust Case Control Consortium.

Chris Wallace, Ming-Zhan Xue, Stephen J. Newhouse, Ana Carolina B. Marçano, Abiodun K. Onipinla, Beverley Burke, Johannie Gungadoo, Richard J. Dobson, Morris Brown, John M. Connell, Anna Dominiczak, G. Mark Lathrop, John Webster, Martin Farrall, Charles Mein, Nilesh J. Samani, Mark J. Caulfield, David G. Clayton, and Patricia B. Munroe
Linkage Analysis Using Co-Phenotypes in the BRIGHT Study Reveals Novel Potential Susceptibility Loci for Hypertension.
Am J Hum Genet. 2006 Aug;79(2):323-31. Epub 2006 Jun 19.

Munroe PB, Wallace C, Xue MZ, B Marcano AC, Dobson RJ, Onipinla AK, Burke B, Gungadoo J, Newhouse SJ, Pembroke J, Brown M, Dominiczak AF, Samani NJ, Lathrop M, Connell J, Webster J, Clayton D, Farrall M, Mein CA, Caulfield M Increased Support for Linkage of a Novel Locus on Chromosome 5q13 for Essential Hypertension in the British Genetics of Hypertension Study.
Hypertension. 2006 Jun 5; [Epub ahead of print]

Bell JT, Wallace C, Dobson R, Wiltshire S, Mein C, Pembroke J, Brown M, Clayton D, Samani N, Dominiczak A, Webster J, Lathrop GM, Connell J, Munroe P, Caulfield M, Farrall M.
Two-dimensional genome-scan identifies novel epistatic loci for essential hypertension.
Hum Mol Genet. 2006 Apr 15;15(8):1365-74. Epub 2006 Mar 16

Sandosh Padmanabhan PhD, Chris Wallace Ph.D, Patricia B. Munroe Ph.D, Richard Dobson BSc, Morris Brown F.R.C.P, Nilesh Samani F.R.C.P, David Clayton B.A, Martin Farrall FRCPath, John Webster F.R.C.P, Mark Lathrop Ph.D, Mark Caulfield F.R.C.P, Anna F. Dominiczak F.R.C.P, John M. Connell F.R.C.P.
Chromosome 2p shows significant linkage to anti-hypertensive response in the British Genetics of Hypertension (BRIGHT) study.
Hypertension. 2006 Mar;47(3):603-8. Epub 2006 Jan 3.

S.J. Newhouse, C. Wallace, R. Dobson, C. Mein, J. Pembroke, M. Farrall, D. Clayton, M. Brown, N. Samani, A. Dominiczak, J.M. Connell, J. Webster, G.M. Lathrop, M. Caulfield, P. B. Munroe.
Haplotypes of the WNK1 gene associate with blood pressure variation in a severely hypertensive population from the British Genetics of Hypertension (BRIGHT) study.
Human Molecular Genetics. Jul 1;14(13):1805-14. Epub 2005 May 11.

Stephens NG, Parsons A, Schofield P, Kelly F, Cheeseman K, Mitchinson MJ and Brown MJ
Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).
Lancet, Vol 347:781-786, 23 March 1996.

Baber NS and Brown MJ
A new opportunity for training in Clinical Pharmacology.
Br J Clin Pharmacol, 41:365-368, 1996.

Laurence DR, Bennett P and Brown MJ
Clinical Pharmacology (Eighth Edition) Churchill Livingstone, 1996

Harach HR, Wheatley T, Smellie WAB and Brown MJ Phaeochromocytoma of the organ of Zuckerkandl invading inferior vena cava
Histopathology, 28:556-559, 1996.

Brown MJ
The causes of essential hypertension
Br J Clin Pharmacol, 42:21-27, 1996.

Wang T, Kaumann AJ and Brown MJ
(-)-Timolol is a more potent antagonist of the positive inotropic effects of (-)-adrenaline than those of (-)-noradrenaline in human atrium.
Br J Clin Pharmacol, 42: 217-223, 1996.

Brown MJ, Castaigne A, Ruilope LM, Mancia G, Rosenthal, de Leeuw PW and Ebner F
INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment
Journal of Human Hypertension, 10 (Supplement 3):S157-S160, 1996.

Hingorani AD, Sharma P, Jia H, Hopper R and Brown MJ
Blood Pressure and the M235T polymorphism of the angiotensinogen gene
Hypertension, 28(5):907-911, 1996.

Ferro A, Hall JA, Dickerson JEC and Brown MJ
A prospective study of the effects of prolonged timolol therapy on *- and *-adrenoceptor and angiotensin II receptor mediated responses in normal subjects.
Br J Clin Pharmacol, 43:301-308, 1997.

Brown MJ
Science, Medicine and the Future: Hypertension
British Medical Journal, 314:1258-1261, 1997

Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A, Schofield WN, Taylor AA and Hill RG
Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists Rizatriptan (MK-462) and Sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols.
Functional Neurology, 12:3-9, 1997.

Medina RA, Cardona-Scanclemente LE, Born GVR and Brown MJ Effect of deoxycorticosterone acetate on blood pressure in relation to accumulation of low-density lipoprotein and fibrinogen by aorta and other tissues of normotensive Wistar rats.
Journal of Hypertension, 15:531-536, 1997.

Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, and Ruilope LM
INSIGHT: Study rationale
International Journal of Clinical Practice, Supplement 92: 39-41, 1997.

Sharma P, Lu F, Rut A and Brown MJ
Structure of human endothelin-2 gene and demonstration of common expression in human right atrial tissue
Biochemical & Biophysical Research Communications, 245:709-712, 1998.

Yasmin, Mascie-Taylor CGN, Brown MJ and Hughes M
The effect of dietary intervention on changes in total cholesterol, blood pressure and weight in a Cambridge study.
International Journal of Clinical Practice, 52(4): 241-245, 1998.

Sharma P, Hingorani A, Jia H, Ashby M, Hopper R, Clayton D, and Brown MJ
Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension
Hypertension, 32(4): 676-82, 1998.

Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T and Ruilope LM
Study population and treatment titration in the International Nifedipine GITS Study: Intervention As a Goal in Hypertension Treatment (INSIGHT).
Journal of Hypertension, 16:2113-2116, 1998.

Brown MJ and Hopper RV
Calcium-channel blockade can mask the diagnosis of Conn's syndrome.
Postgraduate Medical Journal, 75(882):235-236, 1999.

Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR and Brown MJ
Optimisation of antihypertensive treatment by crossover rotation of four major classes
Lancet, 353:2008-13, 1999.

Hockly E and Brown MJ
Homocysteine, vitamins and sex
European Heart Journal, 20:1222-1223, 1999

Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, Lloyd D and Brown MJ
Association of the Gsa gene with essential hypertension and response to b-blockade
Hypertension, 34:8-14, 1999.

Sharma P, Hingorani A, Jia H, Hopper R and Brown MJ Quantitative association between a newly identified molecular variant in the endothelin-2 gene and human essential hypertension. Journal of Hypertension, 17:1281-1287, 1999.

Wang T, Plumpton C and Brown MJ
Selective beta1-adrenoceptor blockade enhances the activity of the stimulatory G-protein in human atrial myocardium.
British Journal of Pharmacology, 128:135-141, 1999.

Wang T and Brown MJ
MRNA quantification by real time TaqMan polymerase chain reaction: validation and comparison with Rnase protection Analytical Biochemistry, 269: 198-201, 1999.

Hingorani AD, Liang CF, Fatibene J et al.
A Common Variant Of The Endothelial Nitric Oxide Synthase Gene (Glu298->Asp) Is A Major Risk Factor For Coronary Artery Disease In The UK.
Circulation, 100: 1515-1520, 1999.

Yasmin and Brown MJ
Similarities and differences between augmentation index and pulse wave velocity in the assessment of arterial stiffness.
Quarterly Journal of Medicine, 92:595-600, 1999.

Laurence DR, Bennett P and Brown MJ
Self Assessment in Clinical Pharmacology (Third Edition)
Churchill Livingstone, 1999

Mitchinson MJ, Stephens NG, Parsons A, Bligh E, Schofield PM, Brown MJ.
Mortality in the CHAOS trial.
Lancet;353(9150):381-2, 1999

Wang T, Plumpton C, Brown MJ.
Selective beta1-adrenoceptor blockade enhances the activity of the stimulatory G-protein in human atrial myocardium.
Br J Pharmacol;128(1):135-41, 1999

Brown MJ, Sharma P and Stevens PA.
Association between diastolic blood pressure and variants of the endothelin-1 and endothelin-2 genes.
J Cardiovasc Pharmacol; 35(4:Suppl2): S41-43, 2000

Brown MJ and Haydock S
Pathoaetiology, Epidemiology and Diagnosis of Hypertension Drugs 2000: 59(Suppl 2) 1-12, 2000

Sharma P, Fatibene J, Ferraro F, Jia H, Monteith S, Brown C, Clayton D, O'Shaughnessy KM.
A genome-wide search for susceptibility loci to human essential hypertension.
Hypertension 35:1291-1296, 2000.

Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Palmer CR, Rosenthal T, and Ruilope LM.
Influence of Diabetes and Type of Hypertension on the Response to Antihypertensive Treatment
Hypertension 2000;35:1038-42.

Jia H, Sharma P, Hopper R, Dickerson C, Lloyd DD, Brown MJ. Beta-adrenoreceptor gene polymorphisms and blood pressure variation with East Anglian Caucasians.
Journal of Hypertension 2000 Jun;18(6):687-93.

Brown MJ, Palmer CR, Castaigne A, de Leeuw P, Mancia G, Rosenthal T and Ruilope LM.
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Lancet, 356:366-372, 2000.

O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, and Brown MJ.
The G389R variant Of the Beta1-Adrenoceptor does not influence Blood Pressure or Response to Beta Blockade in Hypertensive Subjects.
Clinical Science, 99:233-238, 2000.

Brown MJ.
Blood-pressure-lowering treatment.
Lancet. Mar 3;357(9257):715-6, 2001.

Sharma P and Brown MJ.
Neurovascular lessions from a pair of identical twins with cerebral aneurysms.
Postgraduate Medical Journal, 77:197-198, 2001.

Lowe MD, Rowland E, Brown MJ and Grace AA.
b2 adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.
Heart, 86(1): 45-51, 2001.

Brown MJ.
Matching the right drug to the right patient in essential hypertension.
Heart, 86: 113-120, 2001

Sharma P, Wang T, Brown MJ and Schapira AHV.
Fits and Strokes.
The Lancet, 358:120, 2001

Wang T and Brown MJ.
Influence of b1-adrenoceptor blockade on the gene expression of adenylate cyclase subtypes and b-adrenoceptor kinase in human atrium.
Clinical Science, 101, 211-217, 2001.

Deary A, Schumann A, Murfet H, Haydock S, Foo R, Brown M. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Journal of Hypertension, 20:771-777, 2002.

Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ.
Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension.
Clin Sci (Lond) 2002;103:493-9.

Mackenzie IS and Brown MJ
Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment
Clinical Medicine, 2(5): 465-473, 2002.

AJ Sandilands, KM O'Shaughnessy, MJ Brown.
Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 b1-adrenoceptors versus Gly389 b1-adrenoceptors in isolated human atrial myocardium.
British Journal of Pharmacology, 138: 386-392, 2003.

Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, Thom S and Williams B.
Better blood pressure control: how to combine drugs.
Journal of Human Hypertension, 17:81-86, 2003.

Brown MJ.
A rational basis for selection among drugs of the same class. Heart, 89:687-94.

Caulfield M, Munroe P, Pembroke J, et al.
Genome-wide mapping of human loci for essential hypertension.
Lancet 361:2118-23, 2003.

Brown MJ
Implications from hypertension outcome trials for the management of patients with hypertension and diabetes.
Br J Diabetes Vasc Dis 3:245-51, 2003.

Blood Pressure Lowering Treatment Trialists Collaboration.
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
Lancet 2003;362:1527-35.

Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russel GI, Thom S and Williams B.
Better blood pressure control: how to combine drugs.
Journal of Human Hypertension, 17:81-86, 2003.

Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, and Thom SM.
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.
BMJ 328:638-640, 2004.

Yasmin, Falzone R, Brown MJ.
Determinants of arterial stiffness in offspring of families with essential hypertension.
American Journal of Hypertension 2004;17:292-298.

Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR and Glover JF.
Randomised, Double Blind, Placebo Controlled Study of an Angiotensin Immunotherapeutic Vaccine (PMD3117) in Hypertensive Subjects.
Clinical Science (in press).